ASCO: Return to in-person 'zoo that it always was,' with added COVID challenges—and bad shoes FTC launches investigation into major pharmacy benefit managers' business practices Emergent says J&J owes up to $420M for breach of contract. J&J: You want to talk breaches? The top 10 nonprofit health systems by 2021 operating revenue ADA: Dexcom CEO Kevin Sayer on putting M&A on the back burner: 'We've been the organic growth story of the decade' ADA: Embecta's CEO on juggling a double life as a BD spinout and new diabetes tech player Annexon is back with final Huntington's data confirming hypothesis—and no new safety issues to declare Eli Lilly whistleblower says she was fired after reporting manufacturing problems at massive NJ plant Oracle closes $28B deal to buy EHR giant Cerner Apple Watch's 'AFib History' feature ripens with new FDA clearance Sanofi moves into big Cambridge HQ, where 2,500 will work Seres Therapeutics, armed with new safety data, eyes first FDA approval for a microbiome drug AHIP calls for federal agencies to issue extensive guidance to implement ACA 'family glitch' rule Featured Story | By Gabrielle Masson While reveling in the human interaction of being back in person, attendees of the 2022 ASCO annual meeting—which wraps its fifth and final day today—were also faced with the somewhat daunting realization that maybe we don’t quite remember how to be back on-site. read more |
| |
|---|
|
Top Stories By Paige Minemyer Amid growing pressure from Congress to take a closer look at their business practices, the Federal Trade Commission plans to probe six of the largest pharmacy benefit managers in the U.S. read more By Kevin Dunleavy Emergent BioSolutions, which made high-profile errors in the production of two companies’ COVID-19 vaccines and caused millions of doses to be discarded, has notified Johnson & Johnson that it would be on the hook for up to $420 million for bailing on its agreement with the contract manufacturer, Emergent revealed in an SEC filing. read more By Dave Muoio Following a year of pandemic disruptions, the nation's largest nonprofit providers all saw their revenues increase anywhere from 5% to 18% in 2021. read more By Andrea Park "No medical device company goes from $40 million to almost $3 billion organically—we’ve done that,” Dexcom CEO Kevin Sayer told Fierce Medtech. read more By Andrea Park “There are not many companies that start their life after having been in business for 98 years,” Embecta CEO Devdatt Kurdikar told Fierce Medtech during the American Diabetes Association's annual scientific sessions. read more By Annalee Armstrong Investors were troubled by the dropout rate for patients in a phase 2 trial for Annexon’s Huntington’s disease med earlier this year. But now, the biotech is back with the finalized data from that study, with no new discontinuations to report and a solution to mitigate risk. read more By Kevin Dunleavy A whistleblower who was fired by Eli Lilly three years ago has filed suit, alleging that her dismissal came in response to her reporting manufacturing problems at the company’s massive plant in Branchburg, New Jersey. Amrit Mula, the top human resources officer at the plant for eight years, seeks unspecified damages for Lilly’s alleged violation of New Jersey’s employee protection laws. read more By Heather Landi Software maker Oracle cleared the final regulatory hurdle for its pending $28.3 billion acquisition of Cerner, the companies announced Wednesday. The deal is set to close next week. read more By Andrea Park The Apple Watch may already have an impact on a wearer’s heart health, but a new feature set to be added to the smartwatch in its next major update is aiming to give wearers and their providers deeper insights into their cardiac performance. read more By Fraiser Kansteiner Nearly four years after locking up some serious real estate in Cambridge, Massachusetts, Sanofi has cut the ribbon at its massive new campus. read more By Max Bayer Seres Therapeutics has wrapped up an open-label safety trial of its Clostridioides difficile med, clearing its final hurdle before heading to regulators. If approved, it would be the first microbiome-based therapy to hit the market. read more By Robert King Insurance trade group AHIP stressed in comments that a proposed rule to get rid of the ACA's controversial "family glitch" will need to include extensive guidance for plans to implement it. read more | 